HCW Biologics Inc. (NASDAQ:HCWB – Get Rating) was down 1.9% during mid-day trading on Friday . The stock traded as low as $1.97 and last traded at $2.04. Approximately 105,992 shares were traded during trading, an increase of 216% from the average daily volume of 33,561 shares. The stock had previously closed at $2.08.
Wall Street Analyst Weigh In
Separately, Jonestrading started coverage on shares of HCW Biologics in a research report on Monday, November 7th. They set a "buy" rating and a $8.00 price target on the stock.
Get
HCW Biologics alerts:
HCW Biologics Stock Performance
The company has a current ratio of 12.52, a quick ratio of 12.52 and a debt-to-equity ratio of 0.15. The business's 50-day simple moving average is $2.07 and its 200-day simple moving average is $2.25.
HCW Biologics (NASDAQ:HCWB – Get Rating) last released its earnings results on Monday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in HCWB. BlackRock Inc. lifted its position in HCW Biologics by 136.8% during the 1st quarter. BlackRock Inc. now owns 39,583 shares of the company's stock valued at $108,000 after purchasing an additional 22,869 shares during the period. Vanguard Group Inc. lifted its position in HCW Biologics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 95,392 shares of the company's stock valued at $218,000 after purchasing an additional 8,494 shares during the period. Finally, HighTower Advisors LLC increased its stake in shares of HCW Biologics by 2,056.0% in the 1st quarter. HighTower Advisors LLC now owns 215,598 shares of the company's stock valued at $588,000 after acquiring an additional 205,598 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.
HCW Biologics Company Profile
(Get Rating)
HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
Further Reading
- Get a free copy of the StockNews.com research report on HCW Biologics (HCWB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
